|Study Description:||The goal of this clinical research study is to learn about the safety of giving |
GS-1101 (also known as CAL-101) in combination with rituximab, ofatumumab,
bendamustine, fludarabine, everolimus, and bortezomib to patients with NHL,
MCL, or CLL. Researchers also want to learn if this study drug combination can
help to control the disease.